Crinetics Pharmaceuticals Inc
CRNX
Market Cap$2.94B
Close$
$-4.83
111.5% downside
Current Fair Value
111.5% downsideOvervalued by 111.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.94 Billion |
|---|---|
| Enterprise Value | $2.43 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-3.69 |
| Beta | 0.0 |
| Outstanding Shares | 69,600,000 |
| Avg 30 Day Volume | 824,083 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -13.72 |
|---|---|
| PEG | -40.86 |
| Price to Sales | - |
| Price to Book Ratio | 6.02 |
| Enterprise Value to Revenue | 606.13 |
| Enterprise Value to EBIT | -10.93 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
ESG Score
No data
About Crinetics Pharmaceuticals Inc
CEO: R. Scott Struthers